1401P - ASSOR study: oral chemotherapies for oncology practices: a retrospective analysis in the community setting for selected drugs

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Bioethics, Legal, and Economic Issues
Presenter Francoise Grude
Authors F. Grude1, J. Douillard2, C. El Kouri3, P. Donny4, M. Urbanski5, A. Chaslerie4, S. Piau4, H. Bourgeois6, J. Metges7, J. Pivette4
  • 1Ico Paul Papin, Observatoire dédié au Cancer, 49933 - ANGERS/FR
  • 2Medical Oncology, Centre René Gauducheau (ICO) Institut de Cancerologie de l'Ouest, 44805 - St Herblain CEDEX/FR
  • 3Medical Oncology, Catherine de Sienne Institute, 44202 - Nantes/FR
  • 4Pharmacy, DRSM Nantes pays de la Loire, 44000 - Nantes/FR
  • 5Pharmacy, DRSM Rennes Bretagne, 35044 - Rennes/FR
  • 6Medical Oncology, Centre Jean Bernard, clinique Victor Hugo, 72000 - Le Mans/FR
  • 7Medical Oncology, C.H.U. Morvan Institut de Cancerologie et d'Hematologie, 29609 - Brest CEDEX 2/FR



Use of oral chemotherapies is still increasing: currently it represents about 10% of anti-cancer drugs. In 2015, it might be between 25-30%. Oral drugs take part in the increased survival and improvement of patient's quality of life. The Observatory of Cancer Bretagne – Pays de la Loire and the French Regional Health Insurance System had made an observationnal study of oral cancer drug use in theses two area (10% of French Population).


French Regional Health Insurance System has made an extract in its database for patients treated with oral cancer drugs (erlotinib, everolimus, gefitinib, sorafenib, sunitinib) between september 2009 and the end of 2010 (projected three-year follow-up) : prescriber (competence in oncology or not), patient care reimbursed by the health insurance system, gender, age, death, cancer location, type of drug have been collected.


1313 patients (846 men and 437 women) were analysed: 630 patients from Brittany and 683 from Pays de la Loire. According to the National health system, 13.5% of patients did not have optimal reimbursement for care. 30% of patients were under 59 years old, 35% between 60 and 69 and 35% over 70. The more significant cancer location was lung (53%), kidney (26%), digestive tract (19%) and breast (2%). Indeed oral cancer drugs have greatly improved the management of patients with non small cell lung cancer (erlotinib, gefitinib) or kidney cancer (sunitinib, sorafenib, everolimus). More than half of patients (52%) died between 2010 and the end of April 2011. 74% of patients have taken oral drugs for the first time in 2010. 82% of prescriptions have been done according to oral chemotherapy label (10 % for another cancer; 8 % insufficient data). 5% of patient have received more than a first line oral drug during the follow-up (mainly for kidney cancer).


Few data have been published about successive oral chemotherapies and their impact on clinical response, overall survival, toxicities and quality of live. That's why we wanted to complete these data via two dedicated studies about kidney cancer (IVOIRE) and lung cancer (EPINIB). Moreover, compliance of patients treated for a kidney cancer, toxicity of treatment and drugs interaction will be evaluated via a pharmaco economic approach through face to face interview (TOPTACOS).


All authors have declared no conflicts of interest.